Patients with type 2 diabetes who used the GLP-1 receptor agonists liraglutide or semaglutide were at a reduced risk of experiencing cardiorenal events, such as major adverse cardiovascular events and nephropathy, even among those who had a longer diabetes duration and were at a high cardiovascular risk, compared with those on placebo, according to a study presented at the American College of Cardiology's Annual Scientific Session. The findings were based on a post-hoc analysis of data from the LEADER and SUSTAIN-6 trials involving 12,637 participants.
GLP-1 RAs tied to reduced cardiorenal events risk in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.